| ASPsiRNA ID | Pairing of target region (top) and ASP-siRNA (bottom) | Efficacy (mut)(%) | Efficacy (wt) (%) | Diff | Gene | Disease | Mutation | RefSNP | Analysis | Pubmed ID |
|---|---|---|---|---|---|---|---|---|---|---|
| aspsirna3572 | CAGUGGCUCACCAGAUUAC GUCACCGAGUGGUCUAAUG |
75 | 33 | 42 | ACVR1 | Fibrodysplasia Ossificans Progressiva (FOP) | c.617G>A,p.Arg206His | rs12191267 | 
|
|
| aspsirna2339 | AGUGUAACGAGUUCAGAGG UCACAUUGCUCAAGUCUCC |
78 | NA | NA | SOD1 | Amyotrophic Lateral Sclerosis (ALS) | c.256G>C,p.Gly86Arg | rs12191243 |
|
|
| aspsirna2352 | AGUGUAACGAGUUCAGAGG UCACAUUGCUCAAGUCUCC |
80 | NA | NA | SOD1 | Amyotrophic Lateral Sclerosis (ALS) | c.256G>C,p.Gly86Arg | rs12191243 |
|
|
| aspsirna2435 | AACUCCUCCACGCAACUUU UUGAGGAGGUGCGUUGAAA |
47 | 70 | -23 | KRAS | NA | NA | NA |
|
|
| aspsirna3190 | AGUUUCGACAUGUCCUUCC UCAAAGCUGUACAGGAAGG |
60 | 38 | 22 | TP63 | Ectrodactyly-Ectodermal Dysplasia-Clefting syndrome 3 (EEC3) | p.Arg132His,c.394G>A | rs19392114 |
|
|
| aspsirna3083 | CUUUGAGGUGCAUGUUUGUGC GAAACUCCACGUACAAACACG |
65 | 25 | 40 | TP53 | Cancer | NC_000005.10:g.144594367C>A | rs57315468 |
|
|
| aspsirna3089 | CUUUGAGGUGCAUGUUUGUGC GAAACUCCACGUACAAACACG |
70 | 25 | 45 | TP53 | Cancer | NC_000005.10:g.144594367C>A | rs57315468 |
|
|
| aspsirna3095 | CUUUGAGGUGCAUGUUUGUGC GAAACUCCACGUACAAACACG |
72 | 25 | 47 | TP53 | Cancer | NC_000005.10:g.144594367C>A | rs57315468 |
|
|
| aspsirna3096 | UUGUGAGGCACUGCCCCCA AACACUCCGUGACGGGGGU |
68 | 30 | 38 | TP53 | Cancer | c.524G>A ,p.Arg175His | rs28934578 |
|
|
| aspsirna3103 | UUGUGAGGCACUGCCCCCA AACACUCCGUGACGGGGGU |
70 | 30 | 40 | TP53 | Cancer | c.524G>A ,p.Arg175His | rs28934578 |
|
|
| aspsirna2183 | GGAGAAGCCAGAGAUCCUG CCUCUUCGGUCUCUAGGAC |
45 | 70 | -25 | COL6A1 | Ullrich congenital muscular dystrophy (UCMD),Bethlem myopathy (BM) | c.850G>A, p.G284R | rs1219 |
|
|
| aspsirna2176 | GUUUGAGCUAAUGUAUGUG CAAACUCGAUUACAUACAC |
60 | 8 | 52 | HTT | Huntington disease (HD) | c.52CAG(36_39) | rs19392295 |
|
|
| aspsirna3441 | GUUUGAGCUAAUGUAUGUG CAAACUCGAUUACAUACAC |
60 | 8 | 52 | HTT | Huntington disease (HD) | NM_002111.7:c.8163G>A | rs2276881 |
|
|
| aspsirna3451 | GUUUGAGCUAAUGUAUGUG CAAACUCGAUUACAUACAC |
60 | 8 | 52 | HTT | Huntington disease (HD) | NM_002111.7:c.8163G>A | rs2276881 |
|
|
| aspsirna3461 | GUUUGAGCUAAUGUAUGUG CAAACUCGAUUACAUACAC |
60 | 8 | 52 | HTT | Huntington disease (HD) | NM_002111.7:c.8163G>A | rs2276881 |
|
|
| aspsirna3471 | GUUUGAGCUAAUGUAUGUG CAAACUCGAUUACAUACAC |
60 | 8 | 52 | HTT | Huntington disease (HD) | NM_002111.7:c.8163G>A | rs2276881 |
|
|
| aspsirna3481 | GUUUGAGCUAAUGUAUGUG CAAACUCGAUUACAUACAC |
60 | 8 | 52 | HTT | Huntington disease (HD) | NM_002111.7:c.8163G>A | rs2276881 |
|
|
| aspsirna3491 | GUUUGAGCUAAUGUAUGUG CAAACUCGAUUACAUACAC |
60 | 0 | 60 | HTT | Huntington disease (HD) | NM_002111.7:c.8163G>A | rs2276881 |
|
|
| aspsirna1903 | GUGUCACCCUCAGGUGAGGGU CACAGUGGGAGUCCACUCCCA |
Moderate efficacy | Moderate efficacy | Poor discrimination | Myh6 | Human hypertrophic cardiomyopathy (HCM) | c.2384G>A,p.Arg795Gln | rs26760690 |
|
|
| aspsirna0604 | UCAAUUCUCAGCUGGCCUC AGUUAAGAGUCGACCGGAG |
35 | 0 | 35 | KRT9 | Epidermolytic palmoplantar keratoderma (EPPK) | c.488G>A,p.Arg163Gln | rs57758262 |
|
|
| aspsirna0325 | GGUAUUCCCAGGCUCCCAG CCAUAAGGGUCCGAGGGUC |
20 | 10 | 10 | COL7A1 | Dominant dystrophic epidermolysis bullosa(DDEB) | c.6127G>A,p.Gly2043Arg | rs12191283 |
|
|
| aspsirna0337 | GGUAUUCCCAGGCUCCCAG CCAUAAGGGUCCGAGGGUC |
62 | 3 | 59 | COL7A1 | Dominant dystrophic epidermolysis bullosa(DDEB) | c.6127G>A,p.Gly2043Arg | rs12191283 |
|
|
| aspsirna0376 | CAGUGGCUCACCAGAUUAC GUCACCGAGUGGUCUAAUG |
NA | NA | NA | ACVR1 | Fibrodysplasia Ossificans Progressiva (FOP) | c.617G>A,p.Arg206His | rs12191267 |
|
|
| aspsirna0385 | CAGAUUUGGACCUGGCAGU GUCUAAACCUGGACCGUCA |
69 | 38 | 31 | ACVR1 | Fibrodysplasia Ossificans Progressiva (FOP) | c.1067G>A,p.Gly356Asp | rs12191267 |
|
|
| aspsirna0414 | CAGAUUUGGACCUGGCAGUCA GUCUAAACCUGGACCGUCA |
10 | 52 | -42 | ACVR1 | Fibrodysplasia Ossificans Progressiva (FOP) | c.1067G>A,p.Gly356Asp | rs12191267 |
|
|
| aspsirna0415 | CAGAUUUGGACCUGGCAGUUC GUCUAAACCUGGACCGUCA |
33 | 42 | -9 | ACVR1 | Fibrodysplasia Ossificans Progressiva (FOP) | c.1067G>A,p.Gly356Asp | rs12191267 |
|
|
| aspsirna0416 | CAGAUUUGGACCUGGCAG GUCUAAACCUGGACCGUCA |
67 | 69 | -2 | ACVR1 | Fibrodysplasia Ossificans Progressiva (FOP) | c.1067G>A,p.Gly356Asp | rs12191267 |
|
|
| aspsirna0417 | GCAGAUUUGGACCUGGCAGU GUCUAAACCUGGACCGUCA |
60 | 0 | 60 | ACVR1 | Fibrodysplasia Ossificans Progressiva (FOP) | c.1067G>A,p.Gly356Asp | rs12191267 |
|
|
| aspsirna0418 | AGAUUUGGACCUGGCAGU GUCUAAACCUGGACCGUCA |
0 | 6 | -6 | ACVR1 | Fibrodysplasia Ossificans Progressiva (FOP) | c.1067G>A,p.Gly356Asp | rs12191267 |
|
|
| aspsirna0419 | AGAUUUGGACCUGGCAGUC GUCUAAACCUGGACCGUCA |
26 | 74 | -48 | ACVR1 | Fibrodysplasia Ossificans Progressiva (FOP) | c.1067G>A,p.Gly356Asp | rs12191267 |
|
|
| aspsirna0420 | GCAGAUUUGGACCUGGCAGU GUCUAAACCUGGACCGUCA |
0 | 72 | -72 | ACVR1 | Fibrodysplasia Ossificans Progressiva (FOP) | c.1067G>A,p.Gly356Asp | rs12191267 |
|
|
| aspsirna0421 | AGCAGAUUUGGACCUGGCAGU GUCUAAACCUGGACCGUCA |
54 | 40 | 14 | ACVR1 | Fibrodysplasia Ossificans Progressiva (FOP) | c.1067G>A,p.Gly356Asp | rs12191267 |
|
|
| aspsirna0250 | GCUGACUACAGCAUUGCUC CGACUGAUGUCGUAACGAG |
75 | 30 | 45 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 |
|
|
| aspsirna0544 | GCUGACUACAGCAUUGCUC CGACUGAUGUCGUAACGAG |
40 | 86 | -46 | LRRK2 | Parkinsons disease (PD) | c.6055G>A,p.Gly2019Ser | rs34637584 |
|
|
| aspsirna0856 | GUGCCAGCCAUGAACAAUG CACGGUCGGUACUUGUUAC |
68 | 55 | 13 | ATXN7 | Spino Cerebellar Ataxia type-7 (SCA-7) | c.88_90CAG(7_17) | rs193922929 |
|
|
| aspsirna0067 | ACAGUGAUCAUCAUCACCU UGUCACUAGUAGUAGUGGA |
18 | 17 | 1 | APP | Alzheimers disease | c.2010_2011delGAinsTC (p.Lys670_Met671delinsAsnLeu) | rs28186516 |
|
|
| aspsirna0841 | AAGCUGCUGCUACAGAUCAAC UUCGACGACGAUGUCUAGUUG |
NA | NA | NA | HTT | Huntington disease (HD) | c.52CAG(36_39) | rs362273 |
|
|
| aspsirna0054 | GUUUGAGCUAAUGUAUGUG CAAACUCGAUUACAUACAC |
34 | 23 | 11 | HTT | Huntington disease (HD) | c.8163G>A,c.52CAG(36_39) | rs2276881 |
|
|
| aspsirna0340 | GAGUGAUGCAGAAGAAGGG CUCACUACGUCUUCUUCCC |
85 | 10 | 75 | GNE | Sialuria | c.830G>A,p.Arg277Gln | rs12190862 |
|
|
| aspsirna0091 | UUUGUGCACAACUGCGUCA AAACACGUGUUGACGCAGU |
65 | 90 | -25 | PRNP | Prion disease/Creutzfeldt-Jakob disease | c.532G>A,p.Asp178Asn | rs74315403 |
|
|
| aspsirna3506 | UUUGUGCACAACUGCGUCA AAACACGUGUUGACGCAGU |
65 | 90 | -25 | PRNP | Prion disease/Creutzfeldt-Jakob disease | c.532G>A,p.Asp178Asn | rs74315403 |
|
|
| aspsirna0885 | GACCCUCAAAAACAAGUUU CUGGGAGUUUUUGUUCAAA |
59 | 0 | 59 | KRT6a | Pachyonychia congenita (PC) | c.513C>A,p.Asn171Lys | rs59685571 |
|
|
| aspsirna0772 | UUUGGCUUAAAGUUAUAUU AAACCGAAUUUCAAUAUAA |
80 | 35 | 45 | SOD1 | Amyotrophic Lateral Sclerosis (ALS) | c.256G>C, p.Gly86Arg | rs12191243 |
|
|
| aspsirna0773 | GUGGUUGGUGAAGCCUCAG CACCAACCAUUUCGGAGUC |
65 | 11 | 54 | SOD1 | Amyotrophic Lateral Sclerosis (ALS) | c.256G>C, p.Gly86Arg | rs12191243 |
|
|
| aspsirna0774 | UGUGGUUGGCAAAGCCUCA ACACCAACCUUUUCGGAGU |
78 | 45 | 33 | SOD1 | Amyotrophic Lateral Sclerosis (ALS) | c.256G>C, p.Gly86Arg | rs12191243 |
|
|
| aspsirna0568 | GCGACAGUGAUCAUCAUCACCU CGCUGUCACUAGUAGUAGUGGA |
10 | 60 | -50 | APP | Alzheimers disease | c.2149G>A,p.Val717Ile | rs63750264 |
|
|
| aspsirna0572 | CGACAGUGAUCAUCAUCACCU GCUGUCACUAGUAGUAGUGGA |
90 | 70 | 20 | APP | Alzheimers disease | c.2149G>A,p.Val717Ile | rs63750264 |
|
|
| aspsirna1792 | AAUGUGGCCAUGCAUGUGU UUACACCGGUACGUACACA |
NA | 35 | NA | TTR | Amyloidogenic transthyretin amyloidosis | c.148G>A,p.Val50Met | rs28933979 |
|
